[Your role / profession]
- A Computer Engineering student and aspiring AI/ML researcher deeply interested in longevity science, aging biology, healthspan extension, and the application of artificial intelligence to aging research
[Keep]
- Major new research findings on the biology and mechanisms of aging
- Clinical trial results involving interventions targeting aging or age-related biological processes
- Breakthroughs in partial cellular reprogramming, epigenetic rejuvenation, senolytics, rapamycin, NAD+ metabolism, gene therapy, and regenerative medicine
- Research on biological age, epigenetic clocks, aging biomarkers, and multi-omics approaches including genomics, transcriptomics, proteomics, and methylation
- Advances in AI/ML specifically applied to aging biology mechanisms, biological age prediction models, longevity drug discovery, or geroscience research (not general disease diagnostics)
- Important datasets, computational tools, models, or open-source projects relevant to aging biology and longevity research
- News from major longevity companies, research labs, startups, and prominent researchers
- FDA approvals, major clinical milestones, significant funding rounds, or major partnerships related to longevity biotechnology
- High-quality systematic reviews, meta-analyses, and landmark papers on aging and longevity interventions
- Major discoveries related to lifespan extension, healthspan improvement, cellular senescence, age-related diseases, and mechanisms of rejuvenation
[Filter out]
- Generic wellness, diet, exercise, or lifestyle advice without strong scientific relevance to aging research
- Marketing content for supplements, anti-aging products, or treatments without solid clinical evidence
- Celebrity anti-aging routines, beauty industry news, skincare trends, or cosmetic procedures
- Sensationalized longevity claims without credible scientific evidence
- Low-quality studies, press releases that exaggerate findings, or purely speculative anti-aging content
- Diagnostic tools, imaging platforms, or AI applications for age-related diseases (e.g. Alzheimer's, cancer) that focus on detection/diagnosis rather than aging mechanisms or longevity interventions
Filter Strictness80
Translate To
Sources (3)
We support more dynamic and UGC websites now. If a source fails to crawl, please let us know on Discord.
On 12 October, Miami-based Immorta Bio announced the completion of preclinical studies for SenoMune-0257, an AI-designed synthetic peptide nine amino acids long. The molecule is designed to prompt T cells to recognize and eliminate senescent cells, with the first human evaluation planned before year…
Fractyl is concentrating resources on Revita after the REMAIN-1 pivotal cohort met its six-month co-primary endpoint with statistical significance (p=0.0023). The company claims Revita could be the first durable procedural therapy for post-GLP-1 weight maintenance. Plans include an FDA de novo submi…
Cognition Therapeutics announced FDA alignment on key elements of a planned Phase 3 registrational study of Zervimesine (CT1812) for dementia with Lewy bodies (DLB). The study will enroll participants with mild-to-moderate DLB to receive either 100 mg once-daily oral Zervimesine or a placebo for nin…
Immunis was awarded the Grand Prize in the National Academy of Medicine’s Healthy Longevity Global Competition for IMM01-STEM, an investigational multi-active biologic claimed to address biological processes underlying age-related muscle and metabolic decline. The 2026 Grand Prize was open only to p…
Insilico Medicine achieved an early drug discovery milestone for the first of two oncology R&D programs in its AI-driven collaboration with Servier, utilizing its Pharma.AI platform. Announced in early 2026, the collaboration has a total value of up to $888 million, including $32 million in upfront…